NYSEMKT: MLSS
Milestone Scientific Inc Stock Forecast, Predictions & Price Target

Analyst price target for MLSS

Based on 1 analyst offering 12 month price targets for Milestone Scientific Inc

Min Forecast
$1.00+218.47%
Avg Forecast
$1.00+218.47%
Max Forecast
$1.00+218.47%

Should I buy or sell MLSS stock?

Based on 1 analyst offering ratings for Milestone Scientific Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MLSS stock forecasts and price targets.

MLSS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-20

1 of 1

Forecast return on equity

Is MLSS forecast to generate an efficient return?

Company
-188.75%
Industry
20.23%
Market
341.05%
MLSS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MLSS forecast to generate an efficient return on assets?

Company
-56.71%
Industry
15.03%
MLSS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MLSS earnings per share forecast

What is MLSS's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.07
Avg 2 year Forecast
-$0.05
Avg 3 year Forecast
-$0.06

MLSS revenue forecast

What is MLSS's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$10.0M+12.17%
Avg 2 year Forecast
$11.5M+28.69%
Avg 3 year Forecast
$10.7M+19.58%
MLSS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MLSS revenue growth forecast

How is MLSS forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
9.82%
Industry
7.46%
Market
58.02%
MLSS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MLSS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MLSS vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
MLSS$0.31$1.00+218.47%Buy
RVP$0.83N/AN/A
POAI$6.01N/AN/A
BNGO$1.85$7.00+278.38%Buy
HBIO$0.76$2.00+162.81%Buy

Milestone Scientific Stock Forecast FAQ

Is Milestone Scientific Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: MLSS) stock is to Buy MLSS stock.

Out of 1 analyst, 0 (0%) are recommending MLSS as a Strong Buy, 1 (100%) are recommending MLSS as a Buy, 0 (0%) are recommending MLSS as a Hold, 0 (0%) are recommending MLSS as a Sell, and 0 (0%) are recommending MLSS as a Strong Sell.

If you're new to stock investing, here's how to buy Milestone Scientific stock.

What is MLSS's earnings growth forecast for 2025-2027?

(NYSEMKT: MLSS) Milestone Scientific's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 47.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.66%.

Milestone Scientific's earnings in 2025 is -$6,667,190.On average, 4 Wall Street analysts forecast MLSS's earnings for 2025 to be -$5,614,104, with the lowest MLSS earnings forecast at -$6,164,507, and the highest MLSS earnings forecast at -$4,953,622. On average, 4 Wall Street analysts forecast MLSS's earnings for 2026 to be -$4,010,075, with the lowest MLSS earnings forecast at -$5,393,943, and the highest MLSS earnings forecast at -$2,476,811.

In 2027, MLSS is forecast to generate -$4,812,089 in earnings, with the lowest earnings forecast at -$4,623,380 and the highest earnings forecast at -$4,953,622.

What is MLSS's revenue growth forecast for 2025-2027?

(NYSEMKT: MLSS) Milestone Scientific's forecast annual revenue growth rate of 9.82% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.02%.

Milestone Scientific's revenue in 2025 is $8,929,517.On average, 4 Wall Street analysts forecast MLSS's revenue for 2025 to be $787,547,193, with the lowest MLSS revenue forecast at $711,984,807, and the highest MLSS revenue forecast at $858,627,730. On average, 4 Wall Street analysts forecast MLSS's revenue for 2026 to be $903,524,839, with the lowest MLSS revenue forecast at $765,216,581, and the highest MLSS revenue forecast at $1,040,260,519.

In 2027, MLSS is forecast to generate $839,599,533 in revenue, with the lowest revenue forecast at $806,732,647 and the highest revenue forecast at $864,289,012.

What is MLSS's forecast return on assets (ROA) for 2025-2027?

(NYSEMKT: MLSS) forecast ROA is -56.71%, which is lower than the forecast US Medical Instruments & Supplies industry average of 15.03%.

What is MLSS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MLSS price target, the average MLSS price target is $1.00, with the highest MLSS stock price forecast at $1.00 and the lowest MLSS stock price forecast at $1.00.

The Wall Street analyst predicted that Milestone Scientific's share price could reach $1.00 by Nov 20, 2026. The average Milestone Scientific stock price prediction forecasts a potential upside of 218.47% from the current MLSS share price of $0.31.

What is MLSS's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: MLSS) Milestone Scientific's current Earnings Per Share (EPS) is -$0.08. On average, analysts forecast that MLSS's EPS will be -$0.07 for 2025, with the lowest EPS forecast at -$0.08, and the highest EPS forecast at -$0.06. On average, analysts forecast that MLSS's EPS will be -$0.05 for 2026, with the lowest EPS forecast at -$0.07, and the highest EPS forecast at -$0.03. In 2027, MLSS's EPS is forecast to hit -$0.06 (min: -$0.06, max: -$0.06).

What is MLSS's forecast return on equity (ROE) for 2025-2027?

(NYSEMKT: MLSS) forecast ROE is -188.75%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.